Veteran venture investor and operator focused on early-stage technology and healthcare companies, D. Garet Strange brings board-level experience, portfolio construction skills and deal-sourcing networks across the US. Prior roles span startup leadership and venture investing, with a track record of guiding exits, governance and strategic scaling. Known for active engagement in seed-to-Series A rounds, capital allocation discipline and mentorship of founding teams, typically partnering with institutional co-investors.
Veteran venture investor and operator focused on early-stage technology and healthcare companies, D. Garet Strange brings board-level experience, portfolio construction skills and deal-sourcing networks across the US. Prior roles span startup leadership and venture investing, with a track record of guiding exits, governance and strategic scaling. Known for active engagement in seed-to-Series A rounds, capital allocation discipline and mentorship of founding teams, typically partnering with institutional co-investors.
Focuses on early-stage technology and healthcare investments, prioritizing seed to Series A opportunities where founder-market fit and defensible product differentiation are clear. Employs active, board-level stewardship to accelerate go-to-market, governance and follow-on fundraising, while co-investing with institutional partners to diversify risk. Capital allocation favors concentrated, stage-weighted commitments, rigorous due diligence, and milestone-driven follow-ons. Time horizon is growth-oriented multi-year exits; risk discipline emphasizes operational KPIs, capital efficiency and repeatable business models.
Focuses on early-stage technology and healthcare investments, prioritizing seed to Series A opportunities where founder-market fit and defensible product differentiation are clear. Employs active, board-level stewardship to accelerate go-to-market, governance and follow-on fundraising, while co-investing with institutional partners to diversify risk. Capital allocation favors concentrated, stage-weighted commitments, rigorous due diligence, and milestone-driven follow-ons. Time horizon is growth-oriented multi-year exits; risk discipline emphasizes operational KPIs, capital efficiency and repeatable business models.
| Trades 2097 | Longs Won 1350/2097 64% | Profit Factor 16.45 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $267,998.56 |
| Average Win $67,452.52 | Best Trade (Jul 13) $7.27M | Sharpe Ratio -83.5 |
| Average Loss -$7,412.21 | Worst Trade (Mar 31) -$349,354.47 | Z-Score -4.73 (100%) |
| Commissions $0 | Avg. Trade Length 11m 2w 3d | Expectancy $40,783.97 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 47,619 | 42,857 | 38,095 | 33,333 | 28,571 | 23,810 | 19,048 | 14,286 | 9,524 | 4,762 |